Lung cancer
Conditions
Interventions
Experimental group :Total nutritional formula Food for cancer patients for Special medical Use (IMPACT ORAL)
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Subjects voluntarily sign informed consent; 2. Age =18 years old and =85 years old; 3. Patients with non-small cell lung cancer (adenocarcinoma or squamous cell carcinoma, driver negative) with definite pathological diagnosis are to receive first-line platinum-containing two-drug chemotherapy plus immunotherapy; 4. Physical state score (ECOG) of Eastern Tumor Cooperative Group was 0-1; 5. Expected survival of more than 3 months; 6.NRS2002 score =3 points; 7. Laboratory test results during the screening period: 8. Blood routine: ANC=1.5×109/L; PLT=80×109/L; Hb=90 g/L; Blood biochemistry: TBIL=1.5×ULN; ALT and AST=2 x ULN; BUN and Cr=1.5×ULN and creatinine clearance =50mL/min (Cockcroft-Gault formula) 9. Female subjects of reproductive age, male subjects, and male subjects' partners agree to use reliable contraceptive methods (such as abstinence, sterilization, birth control pills, or other contraceptive methods) during the study period.
Exclusion criteria
Exclusion criteria: 1. Patients with other primary tumors and patients with brain metastases; 2. Patients with hematological diseases such as essential thrombocytosis, granulocytosis, aplastic anemia, myelodysplastic syndrome, etc.; 3. Patients with elevated leukocytes and neutrophils caused by infection of other sites; 4. Patients with severe cardiovascular and cerebrovascular diseases or liver and kidney diseases; 5. History of blood loss or blood transfusion due to severe trauma within 1 month before diagnosis; 6. Patients with systemic lupus erythematosus, scleroderma and other autoimmune diseases; 7. Patients with leukocytosis or neutrophilia caused by recent use of hormones; 8. Patients who need long-term antiplatelet drug therapy due to cardiovascular and cerebrovascular diseases; 9. Patients with insufficient clinical data, who refuse to accept follow-up visits or changes in contact information; 10. Patients undergoing or previously receiving chemotherapy, radiotherapy, targeted chemotherapy, arterial embolization chemotherapy, and palliative surgery;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight;Inflammation-related indicators;Immune-related indicators;Metabolism-related index;Fat loss weight, limb skeletal muscle index; | — |
Countries
China
Contacts
Public ContactCong Minghua
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed